Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:385-391
Published online before print December 8, 2005, doi: 10.1161/01.ATV.0000199248.53590.e1
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/2/385    most recent
01.ATV.0000199248.53590.e1v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamon-Fava, S.
Right arrow Articles by Schaefer, E. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamon-Fava, S.
Right arrow Articles by Schaefer, E. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTROGENIC SUBSTANCES, CONJUGATED
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:385.)
© 2006 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Role of the Estrogen and Progestin in Hormonal Replacement Therapy on Apolipoprotein A-I Kinetics in Postmenopausal Women

Stefania Lamon-Fava; Borbala Postfai; Margaret Diffenderfer; Carl DeLuca; John O’Connor, Jr; Francine K. Welty; Gregory G. Dolnikowski; P. Hugh R. Barrett; Ernst J. Schaefer

From the Lipid Metabolism Laboratory (S.L.-F., B.P., M.D., C.D., J.O., E.J.S.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Mass; Division of Cardiology (F.K.W.), Beth Israel Deaconess Medical Center, Harvard University, Boston, Mass; the Mass Spectrometry Laboratory (G.G.D.), Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, Mass; School of Medicine and Pharmacology (P.H.R.B.), University of Western Australia, Perth, Australia.

Correspondence to Stefania Lamon-Fava, Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research, Center on Aging at Tufts University, 711 Washington St, Boston, MA 02111. E-mail stefania.lamon-fava{at}tufts.edu

Objective— Plasma high-density lipoprotein (HDL) cholesterol levels are inversely correlated with the risk of developing coronary heart disease. Hormonal replacement therapy (HRT) affects plasma HDL cholesterol levels, with estrogen increasing HDL cholesterol levels and progestins blunting this effect. This study was designed to assess the mechanism responsible for these effects.

Materials and Methods— HDL apolipoprotein A-I (apoA-I) kinetics were studied in 8 healthy postmenopausal women participating in a double-blind, randomized, crossover study comprising 3 phases: placebo, conjugated equine estrogen (CEE) (0.625 mg/d), and CEE plus medroxyprogesterone acetate (MPA) (2.5 mg/d). Compared with placebo, treatment with CEE resulted in an increase in apoA-I pool size (+20%, P<0.01) because of a significant increase in apoA-I production rate (+47%, P<0.05) and no significant changes in apoA-I fractional catabolic rate. Compared with the CEE alone phase, treatment with the CEE plus MPA resulted in an 8% (P<0.02) reduction in apoA-I pool size and a significant reduction in apoA-I production rate (–13%, P<0.04), without changes in apoA-I fractional catabolic rate.

Conclusion— Postmenopausal estrogen replacement increases apoA-I levels and production rate. When progestin is added to estrogen, it opposes these effects by reducing the production of apoA-I.

We studied the effect of estrogen and progestin in HRT on the metabolism of apoA-I in 8 postmenopausal women. Estrogen increased apoA-I levels and production rate, whereas the progestin counteracted the estrogen effect by reducing apoA-I levels and production rate.


Key Words: apolipoprotein A-I • estrogen • progestin • kinetics stable isotopes




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al.
Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins
Arterioscler. Thromb. Vasc. Biol., September 1, 2008; 28(9): 1672 - 1678.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al.
Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism
J. Lipid Res., August 1, 2007; 48(8): 1746 - 1753.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
M. E. Wierman and W. M. Kohrt
Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials
Reproductive Sciences, May 1, 2007; 14(4): 300 - 314.
[Abstract] [PDF]


Home page
J. Lipid Res.Home page
S. Rashid, B. W. Patterson, and G. F. Lewis
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?
J. Lipid Res., August 1, 2006; 47(8): 1631 - 1642.
[Abstract] [Full Text] [PDF]